CatalYm has reported the successful closure of their Series D financing, raising $150 million.

NexThera Co., Ltd. revealed that it has filed a Phase 1/2a Investigational New Drug application with the U.S. Food and Drug Administration for NT-101.

Zai Lab and argenx Announce China's Approval of Efgartigimod Alfa Subcutaneous Injection for Generalized Myasthenia Gravis.

Eluminex Biosciences Announces Initial Patient Treatment in Phase 1b LOTUS Study of New Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema (DME).

Rznomics Inc. Gains Approval in Australia for Clinical Trial of RNA Editing Therapy Targeting RHO Gene in Retinitis Pigmentosa.

Cytonics Reveals Start Of Initial Human Phase 1 Trial For CYT-108 In Individuals With Knee Osteoarthritis.

Ferring Reveals Initial Findings From Key Phase 3 Study on SI-6603 (condoliase) for Lumbar Disc Herniation at ASPN 2024.

Lexeo Therapeutics Shares Encouraging Early Phase 1/2 Results of LX2006 for Friedreich Ataxia Cardiomyopathy Treatment.

Camurus reveals successful Phase 3 outcomes for the ACROINNOVA 2 trial of octreotide SC depot (CAM2029) in individuals with acromegaly.

AbbVie Files for Regulatory Approval of Upadacitinib (RINVOQ®) with FDA and EMA for Treatment of Giant Cell Arteritis.

YolTech Therapeutics has announced the successful enrollment of the inaugural patient in the Phase I clinical trial of YOLT-201.

Olatec Therapeutics, Inc., a pioneer in the field of selective NLRP3 inhibitors, revealed that individuals with type 2 diabetes mellitus and associated diabetic complications are currently being recruited